- Home
- IMUX vs INVE Comparison
IMUX vs INVE Comparison
Compare IMUX & INVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMUX | INVE |
|---|---|---|
| Founded | 2016 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer peripheral equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.8M | 80.1M |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | IMUX | INVE |
|---|---|---|
| Price | $0.58 | $3.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $6.00 | $5.50 |
| AVG Volume (30 Days) | ★ 1.4M | 48.2K |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $22,015,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11.82 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.55 | $2.86 |
| 52 Week High | $1.39 | $4.07 |
Technical Indicators
Market Signals| Indicator | IMUX | INVE |
|---|---|---|
| Relative Strength Index (RSI) | 33.77 | 53.79 |
| Support Level | $0.58 | $3.40 |
| Resistance Level | $0.70 | $3.79 |
| Average True Range (ATR) | 0.04 | 0.14 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 17.72 | 61.65 |
Price Performance
Historical ComparisonAbout IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.